Department of Physiology, University of Melbourne, Parkville, Vic., Australia.
Neurogastroenterol Motil. 2019 Oct;31(10):e13708. doi: 10.1111/nmo.13708.
The prokinetic effects of 5-HT receptor (5-HT R) agonists have been utilized clinically for almost three decades to relieve symptoms of constipation. Surprisingly, the mechanism(s) of action of these compounds is still being debated. Recent studies highlight luminal 5-HT Rs as an alternative and effective target for these prokinetic agents. These include the study by Shokrollahi et al (2019, Neurogastroenterol Motil, e13598) published in the current issue of Neurogastroenterology and Motility, who found that activation of mucosal 5-HT Rs by intraluminal prucalopride, significantly enhanced propulsive motor patterns in rabbit colon. The authors highlight the idea that development of agonists targeting luminal 5-HT Rs in the colonic mucosa might be more effective and safer in achieving prokinetic effects on intestinal motility. The purpose of this mini-review is to discuss the evidence for luminal 5-HT Rs as an emerging target for prokinetic agents in facilitating propulsive motor patterns in the colon.
5-羟色胺受体(5-HT R)激动剂的促动力作用在临床上已经应用了近三十年,以缓解便秘症状。令人惊讶的是,这些化合物的作用机制仍在争论中。最近的研究强调了腔内 5-HT R 作为这些促动力药物的替代和有效靶点。其中包括 Shokrollahi 等人(2019 年,《神经胃肠病学与运动》,e13598)在本期《神经胃肠病学与运动》上发表的研究,他们发现腔内普芦卡必利激活黏膜 5-HT R,可显著增强兔结肠的推进性运动模式。作者强调了这样一种观点,即开发靶向结肠黏膜腔内 5-HT R 的激动剂,可能在实现对肠道运动的促动力作用方面更有效、更安全。本文的目的是讨论腔内 5-HT R 作为促动力药物的一个新兴靶点,以促进结肠的推进性运动模式。